Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IPIC -- Ignore unavailable to you. Want to Upgrade?

To: Pancho Villa who wrote (1022)	2/5/1998 8:39:00 PM
From: KurtVedder	Read Replies (1) \| Respond to of 1359

<<at best I would expect some kind of limited conditional approval, particularly considering the FDA has already shot itself in the foot when approving Redux [many irregularities have been reported in the approval process of Redux.>> The FDA will NOT base it's decision regarding CerAxon on its past decisions involving IPIC. That is ridiculous. There are no side effects to speak of (unlike Redux) that would cause the FDA to worry about "shooting itself in the foot". True, IPIC could have a problem (unlikely, but possible) with CerAxon based on the fact that there is post-hoc analysis but it would have NOTHING to do with the FDA worrying about approving another IPIC drug. <<The big reason for being of this company was Redux (ask anyone involved with the company) with Redux gone, life will never be the same again.>> Again, nothing could be further from the truth. Even the company itself said (previous to any recalls) that Redux was but a "plank" in the building that is IPIC. Redux was, at best, going to do $80-$100 million a year with Redux (that's if Redux did $1 billion in sales). The reason for investing in IPIC is, was and will be CerAxon, Bucindolol and Pagaclone. That is why I invested. If you feel that Redux was worth investing in for the mediocre revenues it would provide then you should be buying barrels of CEPH (actually, I own quite a bit) since they will do $80 million a year with their eyes closed (no pun intended) with their narcolepsy drug, Provigil. CEPH is about the same price as IPIC. Sure, the Redux revenues would be wonderful right now, but even if there was no recall they could only expect $30-45 million a year from it. Hardly enough to be invested in IPIC unless, of course, they had a great pipeline which it just so happens they do. So, don't kid yourself. Certainly there are hundreds, if not thousands, of attorneys and their investigators searching for dirt regarding IPIC and Redux and not a SINGLE story in 2 months! No new reports of death's or heart problems. Those attorneys are getting rall nervous right about now and they are thinking SETTLEMENT. They want their 33 1/3 contingency fee. NOW. They better find some REAL (as opposed to BS) dirt soon or there ain't gonna be a case. What those attorney's would love now is a good heart attack by someone who took Redux. I have come to learn that these echocardiograms are so sensitive these days that EVERYONE seems to have some sort of valvular problem. Of course, I am exaggerating but this looks like a revisit of 1992 and Prozac hysteria. I remember that Eli Lilly was in big trouble then! I wish I bought shares. Let's save this post too and look at it in a couple of years.